首页> 外文期刊>ACS applied materials & interfaces >Maximizing the Supported Bilayer Phenomenon: Liposomes Comprised Exclusively of PEGylated Phospholipids for Enhanced Systemic and Lymphatic Delivery
【24h】

Maximizing the Supported Bilayer Phenomenon: Liposomes Comprised Exclusively of PEGylated Phospholipids for Enhanced Systemic and Lymphatic Delivery

机译:最大化支持的双层现象:脂质体仅包含聚乙二醇化磷脂,以增强全身和淋巴输送。

获取原文
获取原文并翻译 | 示例
       

摘要

Traditional liposomes degrade into lower-order A micelles when PEGylated to even minor degrees (6-7 mol %) and therefore can offer only limited steric exclusion against opsonization during in vivo delivery. In this work, we present 5 for the first time a liposome coated exclusively by PEGylated, phospholipids, utilizing lipid-coated calcium phosphate (CaF) cores of diverse sizes (10-15 nm, 30-40 nm) as well as varying polyethylene glycol (PEG) chain lengths (3505000 Da). Such folly-PEGylated liposome-calcium phosphate (LCP) particles exhibit a PEG chain length-dependent circulation longevity and robust immune evasion, while facilitating both strong accumulation within solid tumors upon intravenous injection and a more rapid and extensive lymphatic drainage upon subcutaneous administration. Further, these fully-PEGylated liposomes remain amenable to, active targeting strategies which facilitate improved degrees of focused distribution and nanoparticle uptake, represent a lipid packing density commensurate with the formation of a lipid bilayer, and avoid use of scale-limited physical resuspension methods. We expect such improved delivery properties to translate into improved therapeutic safety and efficacy for a variety of systemic and lymphatic diseases.
机译:传统脂质体在聚乙二醇化程度较小时(6-7 mol%)降解为低级A胶束,因此在体内递送过程中只能提供有限的空间排除调理作用。在这项工作中,我们首次展示了5种脂质体,该脂质体仅由聚乙二醇化的磷脂包覆,利用脂质包覆的磷酸钙(CaF)核的大小不同(10-15 nm,30-40 nm)以及各种聚乙二醇(PEG)链长(3505000 Da)。这种全聚乙二醇化脂质体-磷酸钙(LCP)颗粒表现出PEG链长度依赖性的循环寿命和强大的免疫逃逸性,同时促进静脉内注射后实体瘤内的强积累和皮下给药后更迅速和广泛的淋巴引流。此外,这些完全聚乙二醇化的脂质体仍然适合于主动靶向策略,该策略有助于改善集中分布和纳米颗粒摄取的程度,代表与脂质双层形成相对应的脂质堆积密度,并且避免使用规模受限的物理重悬浮方法。我们期望这种改善的递送性质转化成对多种全身和淋巴疾病的改善的治疗安全性和功效。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号